Public Company

Ranbaxy receives final USFDA approval for Glycopyrolate

Ranbaxy Laboratories today announced that it had received final approval from the US Food and Drug Administration (USFDA) to market and manufacture Glycopyrolate tablets. - India to export fresh litchi to US for first time - After mangoes, India to export litchis to US - Ranbaxy Labs launches protein supplement - Ranbaxy, Aurobindo get USFDA nod for migraine drug - Sun Pharma settles patent dispute with Astra Zeneca - Daiichi wins court battle against Mylan, Matrix The drug is indicated for use as adjunctive therapy in the treatment of peptic ulcer. The total annual market sales for Glycopyrolate was 426 million as of June 2009.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Suzlon inks 42 MW contract with Australian firm
Suzlon Energy, one of the leading wind turbine makers, has entered into an agreement with Australia"s Infigen Energy to provide 20 units of wind power generators aggregating to a capacity of 42 MW.
Popular Articles
Modern furniture stores in NY

States can now borrow Rs 21k cr States can now borrow Rs 21k cr BS Reporter / New Delhi August 21, 2009, 0:51 IST
Markets extend losses in noon trades

Sovereign guarantee to NHAI on per case basis
Providing a sovereign guarantee to the National Highways Authority of India’s (NHAI’s) borrowings will be decided on a case-to-case basis by the finance ministry.

© Copyright 2009